Announcements Trials
Browse Landscape

Phase

Phase 1/2 5Phase 2 3Phase 3 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Neoplasms, Squamous Cell 1Head and Neck Neoplasms 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × zalutumumab × Clear all
NCT00542308 2023-08-03

Zalutumumab in Non-curable Patients With SCCHN

Genmab

Phase 2 Completed
90 enrolled 10 charts
Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00460551 2011-12-06

Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer

Genmab

Phase 2 Terminated
13 enrolled 7 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01449357 2011-10-10

Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors

Genmab

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡